Effect of Barbiturate Coma Therapy on Patients with Resistant Intracranial Hypertension: A Meta-Analysis

2023

Closed access Metadata (CSL-JSON)
DOI 10.1109/dasa59624.2023.10286695
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Increased intracranial pressure (ICP) after traumatic brain injury can lead to death of patients. This work aimed to evaluate the impact of barbiturate coma therapy (BCT) on intractable intracranial hypertension patients. We conducted a statistical analysis of studies published up to May 2023. The model showed a positive effect of BCT during treatment., the ICP in the experimental group of patients was 11.29 mmHg lower (on average) than in the control group (mean difference with 95% confidence interval is −11.29 [−16.19., −6.39],$\mathrm{p}-\text{value} < 0.00001$). The model also showed a positive effect of BCT on the patient's neurological condition (MD with a 95% CI is 0.73 [0.37., 1.10],$\mathrm{p}-\text{value} < 0.0001$). BCT significantly reduces intracranial pressure and improves the patient's neurological condition. Although our results are statistically significant, they are based on limited data from four clinical trials. Future studies may evaluate the possible side effects of BCT.